141 related articles for article (PubMed ID: 6712963)
21. Niemann-Pick type II fibroblasts exhibit impaired cholesterol esterification in response to sphingomyelin hydrolysis.
Byers DM; Morgan MW; Cook HW; Palmer FB; Spence MW
Biochim Biophys Acta; 1992 Jan; 1138(1):20-6. PubMed ID: 1737066
[TBL] [Abstract][Full Text] [Related]
22. Chemical and biochemical studies in human fetuses affected with Niemann-Pick disease type A.
Klibansky C; Chazan S; Schoenfeld A; Abramovici A
Clin Chim Acta; 1979 Feb; 91(3):243-50. PubMed ID: 761400
[TBL] [Abstract][Full Text] [Related]
23. Sphingomyelinase and nonspecific phosphodiesterase activities in Epstein-Barr virus-transformed lymphoid cell lines from Niemann-Pick disease A, B and C.
Levade T; Salvayre R; Lenoir G; Douste-Blazy L
Biochim Biophys Acta; 1984 Apr; 793(2):321-4. PubMed ID: 6324871
[TBL] [Abstract][Full Text] [Related]
24. Retroviral-mediated transfer of the human acid sphingomyelinase cDNA: correction of the metabolic defect in cultured Niemann-Pick disease cells.
Suchi M; Dinur T; Desnick RJ; Gatt S; Pereira L; Gilboa E; Schuchman EH
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3227-31. PubMed ID: 1565614
[TBL] [Abstract][Full Text] [Related]
25. Different pathways of uptake and degradation of sphingomyelin by lymphoblastoid cells and the potential participation of the neutral sphingomyelinase.
Levade T; Gatt S; Maret A; Salvayre R
J Biol Chem; 1991 Jul; 266(21):13519-29. PubMed ID: 1649823
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biochemical diagnostics of Niemann-Pick disease.
Maciejko D; Tylki-Szymańska A
Klin Padiatr; 1986; 198(2):103-6. PubMed ID: 3009958
[TBL] [Abstract][Full Text] [Related]
27. Sphingomyelinase activity levels in human peripheral blood leukocytes, using [3H]sphingomyelin as substrate: study of heterozygotes and homozygotes for Niemann-Pick disease variants.
Zitman D; Chazan S; Klibansky C
Clin Chim Acta; 1978 May; 86(1):37-43. PubMed ID: 26487
[TBL] [Abstract][Full Text] [Related]
28. An enzymatic assay for quantifying sphingomyelin in tissues and plasma from humans and mice with Niemann-Pick disease.
He X; Chen F; Gatt S; Schuchman EH
Anal Biochem; 2001 Jun; 293(2):204-11. PubMed ID: 11399033
[TBL] [Abstract][Full Text] [Related]
29. Sphingomyelinase defect in Niemann-Pick disease, type C, fibroblasts.
Besley GT
FEBS Lett; 1977 Aug; 80(1):71-4. PubMed ID: 19295
[No Abstract] [Full Text] [Related]
30. A family with visceral course of Niemann-Pick disease, macular halo syndrome and low sphingomyelin degradation rate.
Sperl W; Bart G; Vanier MT; Christomanou H; Baldissera I; Steichen-Gersdorf E; Paschke E
J Inherit Metab Dis; 1994; 17(1):93-103. PubMed ID: 8051942
[TBL] [Abstract][Full Text] [Related]
31. Chromatofocusing of skin fibroblast sphingomyelinase: alterations in Niemann-Pick disease type C shared by GM1-gangliosidosis.
Vanier MT; Rousson R; Louisot P
Clin Chim Acta; 1983 May; 130(2):155-61. PubMed ID: 6307547
[TBL] [Abstract][Full Text] [Related]
32. Toward gene therapy for Niemann-Pick disease (NPD): separation of retrovirally corrected and noncorrected NPD fibroblasts using a novel fluorescent sphingomyelin.
Dinur T; Schuchman EH; Fibach E; Dagan A; Suchi M; Desnick RJ; Gatt S
Hum Gene Ther; 1992 Dec; 3(6):633-9. PubMed ID: 1482703
[TBL] [Abstract][Full Text] [Related]
33. A fluorometric determination of sphingomyelinase by use of fluorescent derivatives of sphingomyelin, and its application to diagnosis of Niemann-Pick disease.
Gatt S; Dinur T; Barenholz Y
Clin Chem; 1980 Jan; 26(1):93-6. PubMed ID: 6243257
[TBL] [Abstract][Full Text] [Related]
34. A spectrophotometric method for determination of sphingomyelinase.
Gatt S; Dinur T; Barenholz Y
Biochim Biophys Acta; 1978 Sep; 530(3):503-7. PubMed ID: 212111
[TBL] [Abstract][Full Text] [Related]
35. A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death.
Darroch PI; Dagan A; Granot T; He X; Gatt S; Schuchman EH
J Lipid Res; 2005 Nov; 46(11):2315-24. PubMed ID: 16150832
[TBL] [Abstract][Full Text] [Related]
36. Chemical and biochemical studies in fetuses affected with Nieman-Pick disease type A.
Schoenfeld A; Ovadia J; Neri A; Abramovici A; Klibanski C
Prenat Diagn; 1982 Jul; 2(3):177-83. PubMed ID: 6292890
[TBL] [Abstract][Full Text] [Related]
37. Liposome-targeted recombinant human acid sphingomyelinase: Production, formulation, and in vitro evaluation.
Aldosari MH; de Vries RP; Rodriguez LR; Hesen NA; Beztsinna N; van Kuilenburg ABP; Hollak CEM; Schellekens H; Mastrobattista E
Eur J Pharm Biopharm; 2019 Apr; 137():185-195. PubMed ID: 30818011
[TBL] [Abstract][Full Text] [Related]
38. A fluorescence-based, high-throughput sphingomyelin assay for the analysis of Niemann-Pick disease and other disorders of sphingomyelin metabolism.
He X; Chen F; McGovern MM; Schuchman EH
Anal Biochem; 2002 Jul; 306(1):115-23. PubMed ID: 12069422
[TBL] [Abstract][Full Text] [Related]
39. Quantitative evaluation of sphingomyelin and glucosylceramide using matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard. Practical application to tissues from patients with Niemann-Pick disease types A and C, and Gaucher disease.
Fujiwaki T; Tasaka M; Yamaguchi S
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(2):170-6. PubMed ID: 18502707
[TBL] [Abstract][Full Text] [Related]
40. Niemann-Pick disease type D: lipid analyses and studies on sphingomyelinases.
Rao BG; Spence MW
Ann Neurol; 1977 Apr; 1(4):385-92. PubMed ID: 31133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
